The Integrative Management of Treatment-Resistant Depression: A Comprehensive Review and Perspectives
Open accessThe DOI matches its Crossref record; 168 of the 168 references it cites were found in a registry or an index.
Abstract
Background: Major depressive disorder is a prevalent and disabling illness. Notwithstanding numerous advances in the pharmacological treatment of depression, approximately 70% of patients do not remit after first-line antidepressant treatment. Methods: The MEDLINE/PubMed, EMBASE and ClinicalTrials.gov electronic databases were searched from inception to October 1, 2013, for randomized controlled trials (RCT), relevant open-label trials, meta-analyses and ongoing trials of pharmacological and psychotherapeutic approaches to treatment-resistant depression (TRD). Results: Switching to a different antidepressant is a useful option following nonresponse to a first-line agent. Although widely used in clinical practice, there is limited evidence to support antidepressant combination for TRD. Notwithstanding evidence for lithium or T 3 augmentation to be successful in TRD, most studies were carried out when participants were treated with tricyclic antidepressants (TCA). Of the available strategies to augment the response to new-generation antidepressants, the use of some atypical antipsychotics is best supported by evidence. Several novel therapeutic options are currently discussed. Evidence suggests that cognitive therapy (CT) is an effective strategy for TRD. Conclusions: The success of switching to a different antidepressant following a first-line agent is supported by evidence, but there is limited evidence for effective combination strategies. Lithium and T 3 augmentation of TCA have the strongest evidence base for successful treatment of TRD. The use of augmentation of newer-generation antidepressants with atypical antipsychotics is supported by a growing evidence base. Current evidence supports CT as an effective strategy for TRD. There is a need for additional large-scale RCT of TRD. The development of new antidepressants targeting novel pathways opens a promising perspective for the management of TRD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Less common reactions were 'electric-shock' sensation [9,59,61,62] , visual and auditory hallucination [63] , nocturnal enuresis [64] , pruritus [65] , and emesis [6] .”
From Withdrawal Symptoms after Selective Serotonin Reuptake Inhibitor Discontinuation: A Systematic Review (2015) · cites this paper as [63]
In the citing paper
“For example, anti-correlation, which refers to the selective reciprocal activation and deactivation of various brain regions, is critical for proper cognitive functioning.32”
From Cognitive Impairment in Major Depressive Disorder (2019) · cites this paper as [32]
In the citing paper
“In recent decades, the target clinical endpoints for MDD treatment have evolved from response (i.e. a 50 % reduction in severity of depressive symptoms from baseline) to the objective of clinical remission [49].”
From Cognitive remission: a novel objective for the treatment of major depression? (2016) · cites this paper as [49]
Citations
Cites
Murray, C. J. L., Vos, T., Lozano, R., Naghavi, M., Flaxman, A. D., Michaud, C., Ezzati, M., Shibuya, K., Salomon, J. A., Abdalla, S., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61689-4 · Cited by 8,888
A Meta-Analysis of Cytokines in Major Depression
Dowlati, Y., Herrmann, N., Swardfager, W., Liu, H., Sham, L., Reim, E. K., & Lanctôt, K. L. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.09.033 · Cited by 4,729
Inflammation and Its Discontents: The Role of Cytokines in the Pathophysiology of Major Depression
Miller, A. H., Maletic, V., & Raison, C. L. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.11.029 · Cited by 3,848
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Raison, C. L., Rutherford, R. E., Woolwine, B. J., Shuo, C., Schettler, P., Drake, D. F., Haroon, E., & Miller, A. H. (2013) · JAMA Psychiatry · doi:10.1001/2013.jamapsychiatry.4 · Cited by 1,617
Diagnosis and definition of treatment-resistant depression
Fava, M. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00231-2 · Cited by 1,380
Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Beaulieu, S., Alda, M., O’Donovan, C., MacQueen, G., McIntyre, R. S., Sharma, V., et al. (2013) · Bipolar Disorders · doi:10.1111/bdi.12025 · Cited by 1,217
Self-citationTyring, S., Gottlieb, A., Papp, K., Gordon, K., Leonardi, C., Wang, A., Lalla, D., Woolley, M., Jahreis, A., Zitnik, R., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(05)67763-x · Cited by 1,069
Towards a glutamate hypothesis of depression
Sanacora, G., Treccani, G., & Popoli, M. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.07.036 · Cited by 1,036
Bupropion-SR, Sertraline, or Venlafaxine-XR after Failure of SSRIs for Depression
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Stewart, J. W., Nierenberg, A. A., Thase, M. E., Ritz, L., Biggs, M. M., Warden, D., Luther, J. F., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052963 · Cited by 1,033
Medication Augmentation after the Failure of SSRIs for Depression
Trivedi, M. H., Fava, M., Wisniewski, S. R., Thase, M. E., Quitkin, F., Warden, D., Ritz, L., Nierenberg, A. A., Lebowitz, B. D., Biggs, M. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052964 · Cited by 1,002
Fava, M., Rush, A. J., Alpert, J. E., Balasubramani, G. K., Wisniewski, S. R., Carmin, C. N., Biggs, M. M., Zisook, S., Leuchter, A., Howland, R., et al. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.06111868 · Cited by 927
(1997) · PubMed · Cited by 727
Modafinil: a review of neurochemical actions and effects on cognition
Minzenberg, M. J., & Carter, C. S. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301534 · Cited by 713
Maes, M., Leonard, B. E., Myint, A. M., Kubera, M., & Verkerk, R. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.12.017 · Cited by 700
Gaynes, B. N., Warden, D., Trivedi, M. H., Wisniewski, S. R., Fava, M., & Rush, A. J. (2009) · Psychiatric Services · doi:10.1176/ps.2009.60.11.1439 · Cited by 661
Nierenberg, A. A., Fava, M., Trivedi, M. H., Wisniewski, S. R., Thase, M. E., McGrath, P. J., Alpert, J. E., Warden, D., Luther, J. F., Niederehe, G., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.9.1519 · Cited by 559
Nelson, J. C., & Papakostas, G. I. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.09030312 · Cited by 552
Opioid receptors: Distinct roles in mood disorders
Lutz, P.-E., & Kieffer, B. L. (2013) · Trends in Neurosciences · doi:10.1016/j.tins.2012.11.002 · Cited by 542
Marcus, R. N., McQuade, R. D., Carson, W. H., Hennicken, D., Fava, M., Simon, J. S., Trivedi, M. H., Thase, M. E., & Berman, R. M. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31816774f9 · Cited by 518
Preskorn, S. H., Baker, B., Kolluri, S., Menniti, F. S., Krams, M., & Landen, J. W. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31818a6cea · Cited by 518
A Novel Augmentation Strategy for Treating Resistant Major Depression
Shelton, R. C., Tollefson, G. D., Tohen, M., Stahl, S., Gannon, K. S., Jacobs, T. G., Buras, W. R., Bymaster, F. P., Zhang, W., Spencer, K. A., et al. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.1.131 · Cited by 504
Triiodothyronine Augmentation in the Treatment of Refractory Depression: A Meta-analysis
Aronson, R. (1996) · Archives of General Psychiatry · doi:10.1001/archpsyc.1996.01830090090013 · Cited by 488
Connolly, K. R., & Thase, M. E. (2011) · Drugs · doi:10.2165/11587620-000000000-00000 · Cited by 462
Furey, M. L., & Drevets, W. C. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.10.1121 · Cited by 417
Berman, R. M., Marcus, R. N., Swanink, R., McQuade, R. D., Carson, W. H., Corey-Lisle, P. K., & Khan, A. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0604 · Cited by 409
Aspirin: a review of its neurobiological properties and therapeutic potential for mental illness
Berk, M., Dean, O., Drexhage, H., McNeil, J. J., Moylan, S., O'Neil, A., Davey, C. G., Sanna, L., & Maes, M. (2013) · BMC Medicine · doi:10.1186/1741-7015-11-74 · Cited by 391
Self-citationPapakostas, G. I., & Fava, M. (2009) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2008.08.009 · Cited by 382
Lithium Induces Rapid Relief of Depression in Tricyclic Antidepressant Drug Non-Responders
Dé Montigny, C., Grunberg, F., Mayer, A., & Deschenes, J.-P. (1981) · British Journal of Psychiatry · doi:10.1192/bjp.138.3.252 · Cited by 367
Fava, M., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Alpert, J. E., McGrath, P. J., Thase, M. E., Warden, D., Biggs, M., Luther, J. F., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.7.1161 · Cited by 362
McGrath, P. J., Stewart, J. W., Fava, M., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Thase, M. E., Davis, L., Biggs, M. M., Shores-Wilson, K., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.9.1531 · Cited by 350
Pope, H. G., Cohane, G. H., Kanayama, G., Siegel, A. J., & Hudson, J. I. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.1.105 · Cited by 341
Wiles, N., Thomas, L., Abel, A., Ridgway, N., Turner, N., Campbell, J., Garland, A., Hollinghurst, S., Jerrom, B., Kessler, D., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61552-9 · Cited by 340
Abbasi, S.-H., Hosseini, F., Modabbernia, A., Ashrafi, M., & Akhondzadeh, S. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2012.03.033 · Cited by 339
Thase, M. E., Friedman, E. S., Biggs, M. M., Wisniewski, S. R., Trivedi, M. H., Luther, J. F., Fava, M., Nierenberg, A. A., McGrath, P. J., Warden, D., et al. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.5.739 · Cited by 332
Maes, M., Fišar, Z., Medina, M., Scapagnini, G., Nowak, G., & Berk, M. (2012) · Inflammopharmacology · doi:10.1007/s10787-011-0111-7 · Cited by 325
Self-citationJensen, N. H., Rodriguiz, R. M., Caron, M. G., Wetsel, W. C., Rothman, R. B., & Roth, B. L. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301646 · Cited by 316
Papakostas, G. I., Thase, M. E., Fava, M., Nelson, J. C., & Shelton, R. C. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.03.027 · Cited by 308
de Montigny, C. (1983) · Archives of General Psychiatry · doi:10.1001/archpsyc.1983.01790110069012 · Cited by 300
Papakostas, G. I., Mischoulon, D., Shyu, I., Alpert, J. E., & Fava, M. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.09081198 · Cited by 297
Mathew, S. J., Murrough, J. W., aan het Rot, M., Collins, K. A., Reich, D. L., & Charney, D. S. (2010) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145709000169 · Cited by 294
Papakostas, G. I., Fava, M., & Thase, M. E. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.08.010 · Cited by 284
Papakostas, G. I., Shelton, R. C., Zajecka, J. M., Etemad, B., Rickels, K., Clain, A., Baer, L., Dalton, E. D., Sacco, G. R., Schoenfeld, D., et al. (2012) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2012.11071114 · Cited by 275
Spielmans, G. I., Berman, M. I., Linardatos, E., Rosenlicht, N. Z., Perry, A., & Tsai, A. C. (2013) · PLoS Medicine · doi:10.1371/journal.pmed.1001403 · Cited by 275
Serotonergic Drugs for Depression and Beyond
M. Stahl, S., Lee-Zimmerman, C., Cartwright, S., & Ann Morrissette, D. (2013) · Current Drug Targets · doi:10.2174/1389450111314050007 · Cited by 272
A Model of Placebo Response in Antidepressant Clinical Trials
Rutherford, B. R., & Roose, S. P. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2012.12040474 · Cited by 268
Berman, R. M., Fava, M., Thase, M. E., Trivedi, M. H., Swanink, R., McQuade, R. D., Carson, W. H., Adson, D., Taylor, L., Hazel, J., et al. (2009) · CNS Spectrums · doi:10.1017/s1092852900020216 · Cited by 260
Zarate, C. A., Mathews, D., Ibrahim, L., Chaves, J. F., Marquardt, C., Ukoh, I., Jolkovsky, L., Brutsche, N. E., Smith, M. A., & Luckenbaugh, D. A. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.10.019 · Cited by 255
PERSOONS, P., VERMEIRE, S., DEMYTTENAERE, K., FISCHLER, B., VANDENBERGHE, J., VAN OUDENHOVE, L., PIERIK, M., HLAVATY, T., VAN ASSCHE, G., NOMAN, M., et al. (2005) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2005.02535.x · Cited by 253
Berlim, M. T., & Turecki, G. (2007) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2007.03.009 · Cited by 249
Crossley, N. A., & Bauer, M. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0617 · Cited by 246
A double-blind, placebo-controlled study of antidepressant augementation with mirtazapine
Carpenter, L. L., Yasmin, S., & Price, L. H. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01262-8 · Cited by 244
Drevets, W. C., & Furey, M. L. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.11.021 · Cited by 241
Papakostas, G. I., Shelton, R. C., Smith, J., & Fava, M. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0602 · Cited by 241
Thase, M. E., Corya, S. A., Osuntokun, O., Case, M., Henley, D. B., Sanger, T. M., Watson, S. B., & Dubé, S. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0207 · Cited by 228
Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders
Hashimoto, K., Malchow, B., Falkai, P., & Schmitt, A. (2013) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-013-0399-y · Cited by 219
Bauer, M., Pretorius, H. W., Constant, E. L., Earley, W. R., Szamosi, J., & Brecher, M. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04629 · Cited by 210
Staging methods for treatment resistant depression. A systematic review
Ruhé, H. G., van Rooijen, G., Spijker, J., Peeters, F. P. M. L., & Schene, A. H. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.02.020 · Cited by 210
Fava, M., Thase, M. E., & DeBattista, C. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0112 · Cited by 207
Macneil, C. A., Hasty, M. K., Conus, P., & Berk, M. (2012) · BMC Medicine · doi:10.1186/1741-7015-10-111 · Cited by 203
Self-citationSanacora, G., Kendell, S. F., Levin, Y., Simen, A. A., Fenton, L. R., Coric, V., & Krystal, J. H. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.08.037 · Cited by 199
DeBattista, C., Doghramji, K., Menza, M. A., Rosenthal, M. H., Fieve, R. R., & Modafinil in Depression Study Group (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0911 · Cited by 189
Novel therapeutic targets in depression: Minocycline as a candidate treatment
Soczynska, J. K., Mansur, R. B., Brietzke, E., Swardfager, W., Kennedy, S. H., Woldeyohannes, H. O., Powell, A. M., Manierka, M. S., & McIntyre, R. S. (2012) · Behavioural Brain Research · doi:10.1016/j.bbr.2012.07.026 · Cited by 189
Self-citationEl-Khalili, N., Joyce, M., Atkinson, S., Buynak, R. J., Datto, C., Lindgren, P., & Eriksson, H. (2010) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145710000015 · Cited by 185
Adaptation of dialectical behavior therapy skills training group for treatment-resistant depression
Harley, R., Sprich, S., Safren, S., Jacobo, M., & Fava, M. (2008) · Journal of Nervous & Mental Disease · doi:10.1097/nmd.0b013e318162aa3f · Cited by 184
Testosterone replacement therapy for hypogonadal men with SSRI-refractory depression
Seidman, S. N., & Rabkin, J. G. (1998) · Journal of Affective Disorders · doi:10.1016/s0165-0327(97)00168-7 · Cited by 184
Philip, N. S., Carpenter, L. L., Tyrka, A. R., & Price, L. H. (2010) · Psychopharmacology · doi:10.1007/s00213-010-1932-6 · Cited by 182
Venlafaxine and paroxetine in treatment-resistant depression
Gregson, J. (1999) · British Journal of Psychiatry · doi:10.1192/bjp.175.6.591a · Cited by 171
Machado-Vieira, R., Manji, H. K., & Zarate, C. A. (2009) · The Neuroscientist · doi:10.1177/1073858409336093 · Cited by 171
Corya, S. A., Williamson, D., Sanger, T. M., Briggs, S. D., Case, M., & Tollefson, G. (2006) · Depression and Anxiety · doi:10.1002/da.20130 · Cited by 170
Carvalho, L. A., Torre, J. P., Papadopoulos, A. S., Poon, L., Juruena, M. F., Markopoulou, K., Cleare, A. J., & Pariante, C. M. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2012.10.036 · Cited by 167
Barbosa, L., Berk, M., & Vorster, M. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0407 · Cited by 165
Self-citationCreatine metabolism and psychiatric disorders: Does creatine supplementation have therapeutic value?
Allen, P. J. (2012) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2012.03.005 · Cited by 163
Corya, S. A. (2005) · doi:10.4088/jcp.v66n1012 · Cited by 162
Appelberg, B. G., Syvalahti, E. K., Koskinen, T. E., Mehtonen, O.-P., Muhonen, T. T., & Naukkarinen, H. H. (2001) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v62n0608 · Cited by 155
Pérez, V. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.4.375 · Cited by 154
Sepanjnia, K., Modabbernia, A., Ashrafi, M., Modabbernia, M.-J., & Akhondzadeh, S. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2012.58 · Cited by 153
Estrogen replacement therapy in the treatment of major depressive disorder in perimenopausal women.
Rasgon, N., Altshuler, L. L., Fairbanks, L. A., Dunkin, J. J., Davtyan, C., Elman, S., & Rapkin, A. J. (2002) · PubMed · Cited by 150
Landen, M., Bjorling, G., Agren, H., & Fahlen, T. (1998) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v59n1204 · Cited by 149
Papakostas, G. I., Petersen, T. J., Nierenberg, A. A., Murakami, J. L., Alpert, J. E., Rosenbaum, J. F., & Fava, M. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0212 · Cited by 148
Blier, P., & Szabo, S. T. (2005) · PubMed · Cited by 146
McIntyre, A., Gendron, A., & McIntyre, A. (2007) · Depression and Anxiety · doi:10.1002/da.20275 · Cited by 145
Review of Pharmacological Treatment in Mood Disorders and Future Directions for Drug Development
Li, X., Frye, M. A., & Shelton, R. C. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.198 · Cited by 144
Fava, M., Mischoulon, D., Iosifescu, D., Witte, J., Pencina, M., Flynn, M., Harper, L., Levy, M., Rickels, K., & Pollack, M. (2012) · Psychotherapy and Psychosomatics · doi:10.1159/000332050 · Cited by 141
Patkar, A. A., Masand, P. S., Pae, C.-U., Peindl, K., Hooper-Wood, C., Mannelli, P., & Ciccone, P. (2006) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000246212.03530.fd · Cited by 140
Risperidone for Treatment-Refractory Major Depressive Disorder: A Randomized Trial
Mahmoud, R. A., Pandina, G. J., Turkoz, I., Kosik-Gonzalez, C., Canuso, C. M., Kujawa, M. J., & Gharabawi-Garibaldi, G. M. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-147-9-200711060-00003 · Cited by 140
Effects of cognitive therapy on psychological symptoms and social functioning in residual depression
Scott, J., Teasdale, J. D., Paykel, E. S., Johnson, A. L., Abbott, R., Hayhurst, H., Moore, R., & Garland, A. (2000) · British Journal of Psychiatry · doi:10.1192/bjp.177.5.440 · Cited by 139
Brain Bioenergetics and Response to Triiodothyronine Augmentation in Major Depressive Disorder
Iosifescu, D. V., Bolo, N. R., Nierenberg, A. A., Jensen, J. E., Fava, M., & Renshaw, P. F. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.11.020 · Cited by 139
Bauer, M., Tharmanathan, P., Volz, H., Moeller, H., & Freemantle, N. (2009) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-008-0849-0 · Cited by 137
Folinic Acid (Leucovorin) as an Adjunctive Treatment for SSRI-Refractory Depression
Alpert, J. E., Mischoulon, D., Rubenstein, G., Bottonari, K. A., Nierenberg, A. A., & Fava, M. (2002) · Annals of Clinical Psychiatry · doi:10.1023/a:1015271927517 · Cited by 134
Differential metabolic effects of antipsychotic treatments
Haupt, D. W. (2006) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2006.06.003 · Cited by 129
George, T. P., Sacco, K. A., Vessicchio, J. C., Weinberger, A. H., & Shytle, R. D. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318172b49e · Cited by 128
Gałecki, P., Szemraj, J., Bieńkiewicz, M., Zboralski, K., & Gałecka, E. (2009) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.1014 · Cited by 124
Bauer, M., Adli, M., Bschor, T., Pilhatsch, M., Pfennig, A., Sasse, J., Schmid, R., & Lewitzka, U. (2010) · Neuropsychobiology · doi:10.1159/000314308 · Cited by 121
Ravindran, A. V., Kennedy, S. H., O'Donovan, M. C., Fallu, A., Camacho, F., & Binder, C. E. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0112 · Cited by 119
Creatine monohydrate in resistant depression: A preliminary study
Roitman, S., Green, T., Osher, Y., Karni, N., & Levine, J. (2007) · Bipolar Disorders · doi:10.1111/j.1399-5618.2007.00532.x · Cited by 118
Kashani, L., Omidvar, T., Farazmand, B., Modabbernia, A., Ramzanzadeh, F., Tehraninejad, E. S., Ashrafi, M., Tabrizi, M., & Akhondzadeh, S. (2013) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2012.08.010 · Cited by 116
Thase, M. E., Frank, E., Mallinger, A. G., Hamer, T., & Kupfer, D. J. (1992) · PubMed · Cited by 114
Licht, R. W., & Qvitzau, S. (2002) · Psychopharmacology · doi:10.1007/s00213-002-0999-0 · Cited by 112
Carvalho, A. F., Cavalcante, J. L., Castelo, M. S., & Lima, M. C. O. (2007) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2007.00846.x · Cited by 110
Self-citationFava, M., Thase, M. E., DeBattista, C., Doghramji, K., Arora, S., & Hughes, R. J. (2007) · Annals of Clinical Psychiatry · doi:10.1080/10401230701464858 · Cited by 109
Ferreri, M., Lavergne, F., Berlin, I., Payan, C., & Puech, A. J. (2001) · Acta Psychiatrica Scandinavica · doi:10.1034/j.1600-0447.2001.00148.x · Cited by 108
Keitner, G. I., Garlow, S. J., Ryan, C. E., Ninan, P. T., Solomon, D. A., Nemeroff, C. B., & Keller, M. B. (2009) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2008.05.003 · Cited by 108
Evaluating antidepressant therapies: remission as the optimal outcome.
Thase, M. E. (2003) · PubMed · Cited by 106
Nortriptyline for Treatment-Resistant Depression
Nierenberg, A. A., Papakostas, G. I., Petersen, T., Kelly, K. E., Iacoviello, B. M., Worthington, J. J., Tedlow, J., Alpert, J. E., & Fava, M. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0108 · Cited by 106
Alpert, J. E., Papakostas, G., Mischoulon, D., Worthington, J. J., Petersen, T., Mahal, Y., Burns, A., Bottiglieri, T., Nierenberg, A. A., & Fava, M. (2004) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000145339.45794.cd · Cited by 105
Estrogen Augmentation of Antidepressants in Perimenopausal Depression: A Pilot Study
Morgan, M. L., Cook, I. A., Rapkin, A. J., & Leuchter, A. F. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0617 · Cited by 104
Putative neuroprotective agents in neuropsychiatric disorders
Dodd, S., Maes, M., Anderson, G., Dean, O. M., Moylan, S., & Berk, M. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.11.007 · Cited by 104
Self-citationLithium Augmentation of Nortriptyline for Subjects Resistant to Multiple Antidepressants
Nierenberg, A. A., Papakostas, G. I., Petersen, T., Montoya, H. D., Worthington, J. J., Tedlow, J., Alpert, J. E., & Fava, M. (2003) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200302000-00013 · Cited by 103
Reeves, H., Batra, S., May, R. S., Zhang, R., Dahl, D. C., & Li, X. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0805 · Cited by 102
Neurogenic Actions of Atypical Antipsychotic Drugs and Therapeutic Implications
Newton, S. S., & Duman, R. S. (2007) · CNS Drugs · doi:10.2165/00023210-200721090-00002 · Cited by 100
Folates and S-Adenosylmethionine for Major Depressive Disorder
Papakostas, G. I., Cassiello, C. F., & Iovieno, N. (2012) · The Canadian Journal of Psychiatry · doi:10.1177/070674371205700703 · Cited by 99
Clinical practice recommendations for depression
Malhi, G. S., Adams, D., Porter, R., Wignall, A., Lampe, L., O’Connor, N., Paton, M., Newton, L. A., Walter, G., Taylor, A., et al. (2009) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2009.01382.x · Cited by 96
Self-citationOffidani, E., Fava, G. A., Tomba, E., & Baldessarini, R. J. (2013) · Psychotherapy and Psychosomatics · doi:10.1159/000345316 · Cited by 94
Cusin, C., Iovieno, N., Iosifescu, D. V., Nierenberg, A. A., Fava, M., Rush, A. J., & Perlis, R. H. (2013) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.12m08093 · Cited by 93
Lam, R. W., Hossie, H., Solomons, K., & Yatham, L. N. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0308 · Cited by 88
Khajavi, D., Farokhnia, M., Modabbernia, A., Ashrafi, M., Abbasi, S.-H., Tabrizi, M., & Akhondzadeh, S. (2012) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.12m07706 · Cited by 86
Does dopamine dysfunction drive depression?
Malhi, G. S., & Berk, M. (2007) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2007.00969.x · Cited by 86
Self-citationKondo, D. G., Sung, Y.-H., Hellem, T. L., Fiedler, K. K., Shi, X., Jeong, E.-K., & Renshaw, P. F. (2011) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.07.010 · Cited by 86
Mischoulon, D., Nierenberg, A. A., Kizilbash, L., Rosenbaum, J. F., & Fava, M. (2000) · The Canadian Journal of Psychiatry · doi:10.1177/070674370004500509 · Cited by 81
Dunner, D. L., Amsterdam, J. D., Shelton, R. C., Loebel, A., & Romano, S. J. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0714 · Cited by 80
Orengo, C. A., Fullerton, L., & Kunik, M. E. (2005) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/0891988704271767 · Cited by 79
Barbee, J. G., Thompson, T. R., Jamhour, N. J., Stewart, J. W., Conrad, E. J., Reimherr, F. W., Thompson, P. M., & Shelton, R. C. (2011) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09m05355gre · Cited by 78
Augmentation strategies for treatment-resistant depression
Carvalho, A. F., Machado, J. R., & Cavalcante, J. L. (2009) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e32831be9ef · Cited by 78
Self-citationThe impact of statins on psychological wellbeing: a systematic review and meta-analysis
O'Neil, A., Sanna, L., Redlich, C., Sanderson, K., Jacka, F., Williams, L. J., Pasco, J. A., & Berk, M. (2012) · BMC Medicine · doi:10.1186/1741-7015-10-154 · Cited by 78
Self-citationCooper-Kazaz, R., & Lerer, B. (2008) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145707008206 · Cited by 78
TRIVEDI, R. B., Nieuwsma, J. A., & Williams, J. W. (2010) · Journal of General Internal Medicine · doi:10.1007/s11606-010-1608-2 · Cited by 74
Baldomero, E. B., Ubago, J. G., Cercós, C. L., Ruiloba, J. V., Calvo, C. G., López, R. P., & for the ARGOS Study Group (2005) · Depression and Anxiety · doi:10.1002/da.20080 · Cited by 74
5-HT7 Receptor Antagonists as a New Class of Antidepressants
(2007) · Drug News & Perspectives · doi:10.1358/dnp.2007.20.10.1181354 · Cited by 68
Whale, R., Terao, T., Cowen, P., Freemantle, N., & Geddes, J. (2010) · Journal of Psychopharmacology · doi:10.1177/0269881108097714 · Cited by 68
Trivedi, M. H., Thase, M. E., Fava, M., Nelson, J. C., Yang, H., Qi, Y., Tran, Q.-V., Pikalov, A., Carlson, B. X., Marcus, R. N., et al. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n1211 · Cited by 67
Catecholaminergic Strategies for the Treatment of Major Depression
Tremblay, P., & Blier, P. (2006) · Current Drug Targets · doi:10.2174/138945006775515464 · Cited by 65
Lenox-Smith, A. J., & Jiang, Q. (2008) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e3282f424c2 · Cited by 64
Hori, H., & Kunugi, H. (2012) · The Scientific World Journal · doi:10.1100/2012/372474 · Cited by 62
Trivedi, M. H., Thase, M. E., Osuntokun, O., Henley, D. B., Case, M., Watson, S. B., Campbell, G. M., & Corya, S. A. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04064 · Cited by 62
Trivedi, M. H., Cutler, A. J., Richards, C., Lasser, R., Geibel, B. B., Gao, J., Sambunaris, A., & Patkar, A. A. (2013) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13m08360 · Cited by 58
Treatment of tricyclic refractory depression with a monoamine oxidase inhibitor antidepressant.
McGrath, P. J., Stewart, J. W., Harrison, W. M., & Quitkin, F. M. (1987) · PubMed · Cited by 58
The Efficacy and Tolerability of Bupropion in the Treatment of Major Depressive Disorder
Moreira, R. (2011) · Clinical Drug Investigation · doi:10.2165/1159616-s0-000000000-00000 · Cited by 55
Reply to Amitriptyline: Dual-Action Antidepressant?
Thase, M. E. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n1116b · Cited by 52
Michelson, D., Adler, L. A., Amsterdam, J. D., Dunner, D. L., Nierenberg, A. A., Reimherr, F. W., Schatzberg, A. F., Kelsey, D. K., & Williams, D. W. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0414 · Cited by 51
Santos, M. A., Rocha, F. L., & Hara, C. (2008) · The Primary Care Companion to The Journal of Clinical Psychiatry · doi:10.4088/pcc.v10n0302 · Cited by 51
Perry, E. B., Berman, R. M., Sanacora, G., Anand, A., Lynch-Colonese, K., & Charney, D. S. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0215 · Cited by 49
Souery, D., Serretti, A., Calati, R., Oswald, P., Massat, I., Konstantinidis, A., Linotte, S., Kasper, S., Montgomery, S., Zohar, J., et al. (2011) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2011.590225 · Cited by 49
Nelson, J. C., Mankoski, R. E., Baker, R. A., Carlson, B. X., Eudicone, J. M., Pikalov, A., Tran, Q.-V., & Berman, R. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.06.026 · Cited by 46
LEUCHTER, A. F., LESSER, I. M., TRIVEDI, M. H., RUSH, A. J., MORRIS, D. W., WARDEN, D., FAVA, M., WISNIEWSKI, S. R., LUTHER, J. F., PERALES, M., et al. (2008) · Journal of Psychiatric Practice · doi:10.1097/01.pra.0000336754.19566.65 · Cited by 45
Basic Mechanisms of Augmentation of Antidepressant Effects with Thyroid Hormone
Lifschytz, T., Segman, R., Shalom, G., Lerer, B., Gur, E., Golzer, T., & Newman, M. (2006) · Current Drug Targets · doi:10.2174/138945006775515482 · Cited by 45
A Consensus Statement for Safety Monitoring Guidelines of Treatments for Major Depressive Disorder
Dodd, S., Malhi, G. S., Tiller, J., Schweitzer, I., Hickie, I., Khoo, J. P., Bassett, D. L., Lyndon, B., Mitchell, P. B., Parker, G., et al. (2011) · Australian & New Zealand Journal of Psychiatry · doi:10.3109/00048674.2011.595686 · Cited by 45
Self-citationOnce-daily high-dose pindolol for SSRI-refractory depression
Sokolski, K. N., Conney, J. C., Brown, B., & DeMet, E. M. (2004) · Psychiatry Research · doi:10.1016/j.psychres.2003.12.006 · Cited by 42
Pharmacological management of unipolar depression
Malhi, G. S., Hitching, R., Berk, M., Boyce, P., Porter, R., & Fritz, K. (2013) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12122 · Cited by 42
Self-citationStahl, S. M. (2010) · CNS Spectrums · doi:10.1017/s1092852900027334 · Cited by 40
Rogóż, Z., & Skuza, G. (2006) · PubMed · Cited by 38
Segrave, R., & Nathan, P. J. (2005) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.672 · Cited by 38
Systematic review of lamotrigine augmentation of treatment resistant unipolar depression (TRD)
Thomas, S. P., Nandhra, H. S., & Jayaraman, A. (2010) · Journal of Mental Health · doi:10.3109/09638230903469269 · Cited by 37
Dias, R. S., Kerr-Corrêa, F., Moreno, R. A., Trinca, L. A., Pontes, A., Halbe, H. W., Gianfaldoni, A., & Dalben, I. S. (2006) · Menopause · doi:10.1097/01.gme.0000198491.34371.9c · Cited by 34
Pramipexole for stage 2 treatment-resistant major depression: An open study
Inoue, T., Kitaichi, Y., Masui, T., Nakagawa, S., Boku, S., Tanaka, T., Suzuki, K., Nakato, Y., Usui, R., & Koyama, T. (2010) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.07.035 · Cited by 34
Residual symptoms of depression: clinical and theoretical implications
Boulenger, J. (2004) · European Psychiatry · doi:10.1016/j.eurpsy.2004.04.001 · Cited by 34
Lithium and Triiodothyronine Augmentation of Antidepressants
Joffe, R. T., Sokolov, S. T., & Levitt, A. J. (2006) · The Canadian Journal of Psychiatry · doi:10.1177/070674370605101209 · Cited by 32
A Survey of Combination Antidepressant Use in Australia
Horgan, D., Dodd, S., & Berk, M. (2007) · Australasian Psychiatry · doi:10.1080/10398560601109855 · Cited by 31
Self-citationGeretsegger, C., Bitterlich, W., Stelzig-Schöler, R., Stuppaeck, C., Bondy, B., & Aichhorn, W. (2007) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2007.09.002 · Cited by 29
Boulton, D., Balch, A. H., Royzman, K., Patel, C. G., Berman, R., Mallikaarjun, S., & Reeves, R. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108096522 · Cited by 29
Kennedy, S. H., Segal, Z. V., Cohen, N. L., Levitan, R. D., Gemar, M., & Bagby, R. M. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0414 · Cited by 25
Romera, I., Pérez, V., Menchón, J. M., Schacht, A., Papen, R., Neuhauser, D., Abbar, M., Picard, H., & Gilaberte, I. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2012.05.024 · Cited by 24
Karlsson, H., Hirvonen, J., Salminen, J. K., & Hietala, J. A. (2013) · Psychotherapy and Psychosomatics · doi:10.1159/000346143 · Cited by 20
Mischoulon, D., Witte, J. M., Levy, M., Papakostas, G. I., Pet, L. R., Hsieh, W.-H., Pencina, M. J., Ward, S., Pollack, M. H., & D, M. F. M. (2011) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.10m06541 · Cited by 19
Dudley, M., Hadzi-Pavlovic, D., Andrews, D., & Perich, T. (2008) · Australian & New Zealand Journal of Psychiatry · doi:10.1080/00048670802050538 · Cited by 15
Leckman, J. F. (2013) · Psychotherapy and Psychosomatics · doi:10.1159/000345543 · Cited by 12
Combination pharmacotherapy in unipolar depression
Ng, F., Dodd, S., & Berk, M. (2006) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.6.7.1049 · Cited by 11
Self-citationGeretsegger, C., Aichhorn, W., Keglevic, M., Bondy, B., & Stuppaeck, C. (2001) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(01)80237-6 · Cited by 1
Research works printed but not linked: 8
- 10.1176%2fappi.ps.60.11.1439 · doi:10.1176/appi.ps.60.11.1439 · Paper page
- 10.1192%2fbjp.175.1.12 · DOI · Paper page
- 10.1176%2fappi.ajp.163.7.1161 · doi:10.1176/appi.ajp.163.7.1161 · Paper page
- 10.1176%2fappi.ajp.163.9.1531 · DOI
- 10.1176%2fappi.ajp.163.9.1519 · DOI · Paper page
- 10.1159%2f000334112 · DOI
- 10.3109%2f10401230209147396 · doi:10.3109/10401230209147396 · Paper page
- 10.1176%2fappi.ajp.164.5.739 · DOI · Paper page
Cited by
Kennedy, S. H., Lam, R. W., McIntyre, R. S., Tourjman, S. V., Bhat, V., Blier, P., Hasnain, M., Jollant, F., Levitt, A. J., MacQueen, G. M., et al. (2016) · The Canadian Journal of Psychiatry · doi:10.1177/0706743716659417 · Cited by 1,181
“The value of switching between classes or within classes of antidepressants remains controversial.(100) A previous meta-analysis (4 studies, N 1⁄4 1496) found a modest, but statistically significant, remission advantage for patients on an SSRI switched to an antidepressant in a different class (bupropion, mirtazapine,…”
BackgroundSelf-citationFava, G. A., Gatti, A., Belaise, C., Guidi, J., & Offidani, E. (2015) · Psychotherapy and Psychosomatics · doi:10.1159/000370338 · Cited by 436
Cognitive Impairment in Major Depressive Disorder
Pan, Z., Park, C., Brietzke, E., Zuckerman, H., Rong, C., Mansur, R. B., Fus, D., Subramaniapillai, M., Lee, Y., & McIntyre, R. S. (2019) · CNS Spectrums · doi:10.1017/s1092852918001207 · Cited by 320
“The trifecta of cognitive dysfunction, anhedonia, and depressed mood is thought to be a critical mediator of MDD-related functional disability.(6,11) These interconnected domains of depression contribute to self-perpetuating cycles of illness and impairment.”
BackgroundSelf-citationAntidepressant discontinuation reactions: Are preventable and simple to treat
Haddad, P., Lejoyeux, M., & Young, A. (1998) · BMJ · doi:10.1136/bmj.316.7138.1105 · Cited by 286
Dandekar, M. P., Fenoy, A. J., Carvalho, A. F., Soares, J. C., & Quevedo, J. (2018) · Molecular Psychiatry · doi:10.1038/mp.2018.2 · Cited by 266
Self-citation
Metadata
- Authors
- Carvalho, A. F., Berk, M., Hyphantis, T. N., & McIntyre, R. S.
- Affiliations
- Universidade Federal do Ceará (BR)
- Deakin University (AU)
- University of Ioannina (GR)
- University Health Network (CA)
- Venue
- Psychotherapy and Psychosomatics
- Publisher
- S. Karger AG
- Published
- 2014
- Volume
- 83
- Issue
- 2
- Pages
- 70-88
- ISSN
- 0033-3190 (ISSN-L)
- 1423-0348
- OpenAlex
- W1969922688
- Cited by
- 123
- References
- 168
- Citations by year
- 2026: 4 · 2025: 9 · 2024: 12 · 2023: 5 · 2022: 6 · 2021: 11 · 2020: 11 · 2019: 9 · 2018: 12 · 2017: 9 · 2016: 12 · 2015: 15 · 2014: 6
- FWCI
- 1.80
- Type
- journal article
- Language
- en
- Open access
- green
- figshare.com
- Licence
- cc-by
- www.karger.com/Services/SiteLicenses (vor)
- www.karger.com/Services/SiteLicenses (tdm)
- Locations
- Psychotherapy and Psychosomatics (publishedVersion)
- PubMed (publishedVersion)
- Deakin Research Online (Deakin University) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Social Sciences › Psychology › Clinical Psychology › Psychological Treatments and Disorders
- Keywords
- treatment-resistant depression, major depressive disorder, antidepressant switching, antidepressant combination therapy, lithium augmentation, tricyclic antidepressants, atypical antipsychotics, cognitive therapy, newer antidepressants, psychotherapy
- MeSH terms
- Antidepressive Agents, Combined Modality Therapy, Humans, Cognitive Behavioral Therapy, Treatment Outcome, Antidepressive Agents, Second-Generation, Drug Substitution, Depressive Disorder, Treatment-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.